Sellas’ AML Trial to Test AbbVie, Roche and Bristol Myers Combo
ABBV•Sellas’ SLS009 Phase 1/2 AML trial will test a combination of AbbVie’s, Roche’s and Bristol Myers Squibb’s therapies in patients with relapsed or refractory acute myeloid leukemia. Sellas’ stock surged 6% Wednesday, snapping a two-day decline on news of the high-profile drug collaboration.
1. Trial Overview
Sellas’ SLS009 is a Phase 1/2 study enrolling patients with relapsed or refractory acute myeloid leukemia to evaluate safety, tolerability and early efficacy of a multi-agent regimen. The trial uses a dose-escalation design to identify optimal dosing and preliminary response rates.
2. Drug Partners
The regimen incorporates investigational agents from AbbVie, Roche and Bristol Myers Squibb, leveraging distinct mechanisms of action to target leukemic blasts. This collaboration marks a rare three-way pharma combination approach in AML, aiming to overcome single-agent resistance.
3. Market Reaction
On announcement of the collaborative trial, Sellas’ shares jumped 6%, reversing a two-session slide and reflecting investor optimism about validation from major biopharma partners. AbbVie’s stock remained largely unchanged, though the trial highlights the company’s continued focus on hematologic oncology.
4. Next Steps
Sellas plans to report initial safety and biomarker data in late 2026, with potential expansion cohorts to follow if early signals are positive. Analysts will monitor enrollment progress, combination tolerability and any preliminary remission rates for signs of clinical differentiation.
